Longitudinal ctDNA levels and clinical outcomes of first-line (1L) tislelizumab (TIS) plus chemotherapy (chemo) treatment for advanced non-small cell lung cancer (NSCLC) in the RATIONALE-304 and 307 studies
CANCER RESEARCH(2023)
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要